Orion Oyj posted a 21.8% revenue increase to €939.3 million and a 59.6% rise in operating profit to €291.3 million for the first half of 2026. The company highlighted progress in its ODM-212 cancer drug development and FDA approval for its Animal Health product Tessie®. Orion raised its 2026 revenue forecast to €2.0-2.1 billion and operating profit to €650-750 million, citing strong sales growth and improved profitability driven by Nubeqa royalties. The outlook reflects confidence in continued growth despite risks from supply chains and regulatory changes.
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed client-serving trades involving 21,254 ordinary shares bought and sold on July 16, 2026. The transactions occurred at prices between 936 and 948 currency units per shar...
Man Group PLC has publicly disclosed holding a 1.62% interest in Senior Plc's ordinary shares as of July 16, 2026, according to the UK Takeover Code requirements. This disclosure includes their ownership of 6,829,122 shares through cash-settled deriv...
ResearchAndMarkets.com released a comprehensive report analyzing over 1,230 bioinformatics collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, including upfront payments, milestones, royaltie...
Dimensional Fund Advisors Ltd has publicly disclosed holding a 1.7% ownership stake in Rotork PLC, amounting to 13,909,604 ordinary shares as of July 16, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, which requires investors with...
The global Indium Phosphide (InP) wafer market is projected to expand from USD 202.21 million in 2025 to USD 679.76 million by 2035, growing at a CAGR of 12.89%. Growth is fueled by rising demand in AI data centers, 5G and upcoming 6G infrastructure,...
